Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W, Sehouli J; North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer. Koensgen D, et al. Among authors: lichtenegger w. Cancer Chemother Pharmacol. 2008 Aug;62(3):393-400. doi: 10.1007/s00280-007-0617-2. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922272 Clinical Trial.
First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W; Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Among authors: lichtenegger w. Gynecol Oncol. 2002 May;85(2):321-6. doi: 10.1006/gyno.2002.6623. Gynecol Oncol. 2002. PMID: 11972395 Clinical Trial.
Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J, Stengel D, Mustea A, Camara O, Keil E, Elling D, Ledwon P, Christiansen B, Klare P, Gebauer G, Schwarz M, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie. Sehouli J, et al. Among authors: lichtenegger w. Cancer Chemother Pharmacol. 2008 Feb;61(2):243-50. doi: 10.1007/s00280-007-0466-z. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2008. PMID: 17393164 Clinical Trial.
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). Oskay-Oezcelik G, et al. Among authors: lichtenegger w. Anticancer Res. 2008 Mar-Apr;28(2B):1329-34. Anticancer Res. 2008. PMID: 18505074 Free article. Clinical Trial.
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W. Sehouli J, et al. Among authors: lichtenegger w. J Clin Oncol. 2008 Jul 1;26(19):3176-82. doi: 10.1200/JCO.2007.15.1258. J Clin Oncol. 2008. PMID: 18591555 Clinical Trial.
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G. Sehouli J, et al. Among authors: lichtenegger w. Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7. Cancer Chemother Pharmacol. 2010. PMID: 20054549 Clinical Trial.
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. Sehouli J, et al. Among authors: lichtenegger w. J Clin Oncol. 2011 Jan 10;29(2):242-8. doi: 10.1200/JCO.2009.27.8911. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115872 Clinical Trial.
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group. Sehouli J, et al. Among authors: lichtenegger w. Ann Oncol. 2002 Nov;13(11):1749-55. doi: 10.1093/annonc/mdf294. Ann Oncol. 2002. PMID: 12419747 Free article. Clinical Trial.
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Among authors: lichtenegger w. Onkologie. 2004 Feb;27(1):58-64. doi: 10.1159/000075607. Onkologie. 2004. PMID: 15007250 Clinical Trial.
205 results